Abner Herrman & Brock LLC raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,392 shares of the company’s stock after buying an additional 1,185 shares during the period. Abner Herrman & Brock LLC’s holdings in Thermo Fisher Scientific were worth $2,925,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of TMO. Guyasuta Investment Advisors Inc. increased its stake in shares of Thermo Fisher Scientific by 2.2% in the third quarter. Guyasuta Investment Advisors Inc. now owns 120,027 shares of the company’s stock worth $19,091,000 after buying an additional 2,529 shares in the last quarter. Cryder Capital Partners LLP increased its stake in Thermo Fisher Scientific by 31.8% in the third quarter. Cryder Capital Partners LLP now owns 164,704 shares of the company’s stock valued at $26,198,000 after buying an additional 39,780 shares during the period. Allegis Investment Advisors LLC increased its stake in Thermo Fisher Scientific by 6.3% in the third quarter. Allegis Investment Advisors LLC now owns 5,550 shares of the company’s stock valued at $883,000 after buying an additional 328 shares during the period. Commerce Bank increased its stake in Thermo Fisher Scientific by 4.1% in the third quarter. Commerce Bank now owns 203,017 shares of the company’s stock valued at $32,292,000 after buying an additional 7,964 shares during the period. Finally, Toronto Dominion Bank increased its stake in Thermo Fisher Scientific by 237.5% in the third quarter. Toronto Dominion Bank now owns 13,188 shares of the company’s stock valued at $2,098,000 after buying an additional 9,281 shares during the period. 86.28% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific Inc. (NYSE:TMO) traded up 0.68% during midday trading on Tuesday, hitting $141.27. The company had a trading volume of 2,576,593 shares. The firm has a 50-day moving average price of $149.29 and a 200-day moving average price of $151.92. The company has a market cap of $55.81 billion, a price-to-earnings ratio of 28.24 and a beta of 1.24. Thermo Fisher Scientific Inc. has a 12 month low of $119.75 and a 12 month high of $160.68.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, October 27th. The company reported $2.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.97 by $0.06. Thermo Fisher Scientific had a return on equity of 14.95% and a net margin of 11.10%. The firm had revenue of $4.49 billion for the quarter, compared to analyst estimates of $4.39 billion. During the same quarter in the prior year, the company earned $1.80 EPS. Thermo Fisher Scientific’s revenue was up 8.9% on a year-over-year basis. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post $8.25 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, January 16th. Shareholders of record on Thursday, December 15th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date of this dividend is Tuesday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 12.00%.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/29/abner-herrman-brock-llc-acquires-1185-shares-of-thermo-fisher-scientific-inc-tmo.html.

Several research firms have recently weighed in on TMO. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $178.00 target price for the company in a research report on Monday, August 1st. Bank of America Corp. set a $180.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Friday, October 7th. Jefferies Group restated a “hold” rating on shares of Thermo Fisher Scientific in a research note on Thursday, August 4th. JPMorgan Chase & Co. initiated coverage on Thermo Fisher Scientific in a research note on Thursday, September 22nd. They set an “overweight” rating and a $180.00 price target on the stock. Finally, Leerink Swann initiated coverage on Thermo Fisher Scientific in a research note on Thursday, November 10th. They set an “outperform” rating and a $175.00 price target on the stock. Two analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $164.37.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 30,000 shares of the stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $151.17, for a total value of $4,535,100.00. Following the sale, the chief executive officer now owns 308,647 shares of the company’s stock, valued at approximately $46,658,166.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 28,797 shares of the stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $151.01, for a total value of $4,348,634.97. Following the completion of the sale, the chief executive officer now directly owns 307,444 shares in the company, valued at approximately $46,427,118.44. The disclosure for this sale can be found here. 0.52% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Receive News & Stock Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related stocks with our FREE daily email newsletter.